A Phase 1/2 Study of HDAC Inhibitor, Mocetinostat, in Co

Project: Research project

Project Details

Description

A Phase 1/2 Study of HDAC Inhibitor, Mocetinostat, in Combination With PD-L1 Inhibitor, Durvalumab, in Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer
StatusActive
Effective start/end date4/30/166/30/20

Funding

  • MIRATI THERAPEUTICS, INC.

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.